Array BioPharma Names Patricia Henahan CFO - Quick Facts

(RTTNews) - Array BioPharma (ARRY) announced the appointment of Patricia Henahan as its Chief Financial Officer or CFO. Henahan has extensive financial experience in the biopharmaceutical industry including leadership roles at Hospira, AstraZeneca, Eli Lilly and MedImmune.

Prior to joining Array, Henahan was Vice President of Finance for Hospira's $3 billion U.S. pharmaceutical-focused business. During her tenure, Hospira delivered double-digit profit growth and achieved its highest ever U.S. market share and revenue level.

The company said Henahan joins Array in advance of several significant milestones, including top-line results from the NEMO and COLUMBUS Phase 3 pivotal trials and projected regulatory filings of wholly-owned binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor.

Prior to her role at Hospira, Henahan was Chief Financial Officer of iPR Pharmaceuticals, Inc., AstraZeneca Group, from 2009 to 2013, where she was responsible for revenue of $5 billion, Array noted.